75 results
8-K
EX-99.1
BFRI
Biofrontera Inc
15 Mar 24
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
5:20pm
study of safety and efficacy of Ameluz® and RhodoLED® XL for treatment of AK on the extremities, neck and trunk.
“I am pleased to announce 2023
8-K
EX-10.1
BFRI
Biofrontera Inc
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
, inventions, methods, test data, including but not limited to, biological, chemical, pharmacological, biochemical, pharmaceutical, toxicological, safety … with the Lamp will be agreed upon in separate Safety Data Exchange Agreements that will be closed in due time after signing this Agreement, but before
8-K
EX-10.2
a73 zjqk4jcqvzv
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
EX-99.1
55rmkfu
5 Feb 24
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz® to Permit Up to Three Tubes per Use
5:25pm
8-K
EX-99.1
upp095a70
9 Nov 23
Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
5:15pm
8-K
EX-10.1
o5z1s
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
8-K
EX-10.2
8ueek6 1kq
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
424B4
257k9
1 Nov 23
Prospectus supplement with pricing info
5:09pm
8-K
EX-99.1
86yhfmkbjxunh8
10 Oct 23
Patent Application Filed with Potential to Extend Ameluz® Protection to 2043
9:15am